ArticleBMJ health & care informatics2026
Development and evaluation of AI-based clinical decision support system for streamlining breast multidisciplinary team meetings.
Article in BMJ health & care informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMultidisciplinary team (MDT) meetings are key to delivering cancer care. Increasing caseload and limited resources make them less effective and unsustainable. The aim of this quality improvement project was to assess novel artificial intelligence-based clinical decision support (CDS) technology to develop and validate standard of care (SoC) to streamline the breast MDT meetings in a tertiary cancer centre.
methodsA clinical governance group of the MDT approved international guidelines used to develop SoC. Deontics CDS was assessed for its suitability to apply the SoC pathway for benign and malignant breast disease with the exclusion of metastatic and recurrent cancer.
resultsPatients discussed over the preceding 16 months were added to the platform in cohorts of 50 women: two consisting of 50 women each diagnosed with benign disease (benign A and B: n=100) and three consisting of 50 women each diagnosed with malignant disease (cancer A, B and C: n=150). Concordance between the blinded MDT decision outcomes and SoC recommendations was analysed. This stepwise approach identified knowledge gaps in SoC and refined the CDS. Concordance improved from 82% to 100% in benign and from 94% to 100% in malignant cases. DISCUSSION: A sequential process of validating the SoC with data derived from the development of evidence-based SoC protocols based on international guidelines resulted in a final 100% concordance rate between the platform and MDT recommendations for both benign and malignant disease.
conclusionsCDS technology could be a milestone in using SoC to deliver a sustainable clinical decision pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.